Evidence map›Paper›PMID 25007872›Full record

ArticleAmerican journal of physiology. Renal physiology2014

Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.

Mary Taub, Robert Parker, Paremala Mathivanan, Muhamad Asnawi Mohd Ariff, Trina Rudra

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mary TaubBiochemistry Department, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York biochtau@buffalo.edu.
Robert ParkerBiochemistry Department, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York.
Paremala MathivananBiochemistry Department, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York.
Muhamad Asnawi Mohd AriffBiochemistry Department, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York.
Trina RudraBiochemistry Department, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York.
University at Buffalo, State University of New York · US

Funding

PHITPO CDC HHS 1R01-HK-69676-01
6 · The paper itself

Abstract

The actions of prostaglandin E2 (PGE2) in the kidney are mediated by G protein-coupled E-prostanoid (EP) receptors, which affect renal growth and function. This report examines the role of EP receptors in mediating the effects of PGE2 on Madin-Darby canine kidney (MDCK) cell growth. The results indicate that activation of Gs-coupled EP2 and EP4 by PGE2 results in increased growth, while EP1 activation is growth inhibitory. Indeed, two EP1 antagonists (ONO-8711 and SC51089) stimulate, rather than inhibit, MDCK cell growth, an effect that is lost following an EP1 knockdown. Similar observations were made with M1 collecting duct and rabbit kidney proximal tubule cells. ONO-8711 even stimulates growth in the absence of exogenous PGE2, an effect that is prevented by ibuprofen (indicating a dependence upon endogenous PGE2). The involvement of Akt was indicated by the observation that 1) ONO-8711 and SC51089 increase Akt phosphorylation, and 2) MK2206, an Akt inhibitor, prevents the increased growth caused by ONO-8711. The involvement of the EGF receptor (EGFR) was indicated by 1) the increased phosphorylation of the EGFR caused by SC51089 and 2) the loss of the growth-stimulatory effect of ONO-8711 and SC51089 caused by the EGFR kinase inhibitor AG1478. The growth-stimulatory effect of ONO-8711 was lost following an EGFR knockdown, and transduction of MDCK cells with a dominant negative EGFR. These results support the hypothesis that 1) signaling via the EP1 receptor involves Akt as well as the EGFR, and 2), EP1 receptor pharmacology may be employed to prevent the aberrant growth associated with a number of renal diseases.

Indexed as

AnimalsBridged Bicyclo CompoundsCaproatesCell ProliferationDogsErbB ReceptorsHeterocyclic Compounds, 3-RingHydrazinesIbuprofenKidneyMadin Darby Canine Kidney CellsOxazepinesProto-Oncogene Proteins c-aktQuinazolinesReceptors, Prostaglandin E, EP1 SubtypeReceptors, Prostaglandin E, EP2 SubtypeBridged Bicyclo CompoundsCaproatesErbB ReceptorsHeterocyclic Compounds, 3-RingHydrazinesIbuprofenMK 2206ONO 8711OxazepinesProto-Oncogene Proteins c-aktQuinazolinesReceptors, Prostaglandin E, EP1 SubtypeReceptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 SubtypeRTKI cpdSC 51089TyrphostinsEP receptorskidney epithelial cell growthprostaglandin E2

Identifiers

PMID25007872
PMCPMC4154115
OpenAlexW1990218086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.